| 摘要 |
The present invention relates to (a) the establishment of a direct consequence to the mitochondrial import of phosphorylated p66<ShcA >and its association with prohibitin, and (b) to a potential function for the prohibitin-p66<ShcA >complex in the mitochondrial membrane depolarization process that governs metabolic events such as bioenergetics and free radical formation. The present invention can also be employed as a tool for identifying pharmaceutically active compounds that disrupt the prohibitin-p66<ShcA >interaction, thereby providing treatment options for aging-related diseases such as diabetes, cardiovascular, osteoporosis, cancer and neurodegenerative diseases.
|
